View Financial Health3-D Matrix 배당 및 자사주 매입배당 기준 점검 0/63-D Matrix 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.9%자사주 매입 수익률총 주주 수익률-0.9%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 103-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 20263-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026공시 • Oct 203-D Matrix, Ltd. Announces Collaborative Research with Harvard Drives Regenerative Medicine Breakthrough3-D Matrix, Ltd. has been engaged in the development of medical products based on its proprietary self-assembling peptide technology. In the field of regenerative medicine, the Company has been promoting collaborative research with leading academic institutions worldwide. The company announced that the results of joint research with Harvard University, employing the Company's self-assembling peptide "RADA16," was recently published in the internationally renowned scientific journal Science. This publication marks a advancement in addressing fundamental challenges in cardiac regenerative therapy. Conventional transplantation of iPSC-derived cardiomyocytes has been hindered by the occurrence of life-threatening arrhythmias caused by abnormal automaticity (spontaneous contraction) of the transplanted cells. In this study, the company successfully suppressed this arrhythmogenic automaticity through co-administration of the Company's self- assemblingling peptide. Furthermore, using a technology of flexible nanoelectronics, company were the first in the world to visualize how transplanted cells electrically integrate and synchronize with host cardiac tissue. In addition, the study demonstrated that the peptide significantly accelerated the maturation of the transplanted cells, shifting their gene expression profile from a fetal-like to an adult-like state, and markedly enhanced the organization of sarcomeres, the contractile units of cardiomyocytes. In addition, functional vascularization, which was difficult to verify, was clearly confirmed. The transplanted tissue formed functional anastomoses with host vasculature, establishing a stable supply of oxygen and nutrients, which greatly improved cell survival. This technology is expected not only to accelerate the practical application of iPSC-based therapies for heart disease, but also to drive progress in regenerative medicine for various tissues requiring vascularization. This research was conducted within the existing development budget and will have no impact on full-year financial forecast or current mid-term business plan. The Company will continue to collaborate globally with leading academic institutions to contribute to solving unmet medical needs and to bring new medical value to society through innovation in regenerative medicine.공시 • Sep 233-D Matrix, Ltd. to Report Q2, 2026 Results on Dec 11, 20253-D Matrix, Ltd. announced that they will report Q2, 2026 results on Dec 11, 2025공시 • Jul 113-D Matrix, Ltd. announced that it has received ¥1.103184 billion in funding from CVI Investments, Inc.On July 10, 2025, 3-D Matrix Co., Ltd. closed the transaction.공시 • Jul 093-D Matrix, Ltd. to Report Q1, 2026 Results on Sep 11, 20253-D Matrix, Ltd. announced that they will report Q1, 2026 results on Sep 11, 2025공시 • Jun 123-D Matrix, Ltd., Annual General Meeting, Jul 24, 20253-D Matrix, Ltd., Annual General Meeting, Jul 24, 2025.공시 • Apr 113-D Matrix, Ltd. to Report Fiscal Year 2025 Results on Jun 12, 20253-D Matrix, Ltd. announced that they will report fiscal year 2025 results on Jun 12, 2025공시 • Jan 173-D Matrix, Ltd. to Report Q3, 2025 Results on Mar 13, 20253-D Matrix, Ltd. announced that they will report Q3, 2025 results on Mar 13, 2025공시 • Oct 293-D Matrix, Ltd. to Report Q2, 2025 Results on Dec 12, 20243-D Matrix, Ltd. announced that they will report Q2, 2025 results on Dec 12, 2024공시 • Aug 033-D Matrix, Ltd. to Report Q1, 2025 Results on Sep 12, 20243-D Matrix, Ltd. announced that they will report Q1, 2025 results on Sep 12, 2024공시 • Jun 153-D Matrix, Ltd., Annual General Meeting, Jul 25, 20243-D Matrix, Ltd., Annual General Meeting, Jul 25, 2024.공시 • May 173-D Matrix, Ltd. to Report Fiscal Year 2024 Results on Jun 13, 20243-D Matrix, Ltd. announced that they will report fiscal year 2024 results on Jun 13, 2024공시 • Apr 043-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.On April 4, 2024, 3-D Matrix, Ltd., closed the transaction.공시 • Mar 203-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement to issue 260,000 stock acquisition rights at an issue price of ¥87 per stock acquisition right for the gross proceeds of ¥22,620,000 on March 19, 2024. The transaction will include participation from returning investor, CVI Investments, Inc. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company.공시 • Mar 013-D Matrix, Ltd. to Report Q3, 2024 Results on Mar 13, 20243-D Matrix, Ltd. announced that they will report Q3, 2024 results on Mar 13, 2024공시 • Nov 133-D Matrix, Ltd. to Report Q2, 2024 Results on Dec 13, 20233-D Matrix, Ltd. announced that they will report Q2, 2024 results on Dec 13, 2023공시 • Sep 023-D Matrix, Ltd. to Report Q1, 2024 Results on Sep 13, 20233-D Matrix, Ltd. announced that they will report Q1, 2024 results on Sep 13, 2023공시 • Jun 163-D Matrix, Ltd., Annual General Meeting, Jul 27, 20233-D Matrix, Ltd., Annual General Meeting, Jul 27, 2023.공시 • May 103-D Matrix, Ltd. to Report Fiscal Year 2023 Results on Jun 14, 20233-D Matrix, Ltd. announced that they will report fiscal year 2023 results on Jun 14, 2023공시 • Feb 163-D Matrix, Ltd. to Report Q3, 2023 Results on Mar 17, 20233-D Matrix, Ltd. announced that they will report Q3, 2023 results on Mar 17, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 DMTR.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: DMTR.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장3-D Matrix 배당 수익률 vs 시장DMTR.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (DMTR.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (DMTR.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 DMTR.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 DMTR.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 DMTR.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: DMTR.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 19:46종가2026/03/03 00:00수익2026/01/31연간 수익2025/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스3-D Matrix, Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kiyokazu YamazakiIchiyoshi Research Institute Inc.
공시 • May 103-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 20263-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026
공시 • Oct 203-D Matrix, Ltd. Announces Collaborative Research with Harvard Drives Regenerative Medicine Breakthrough3-D Matrix, Ltd. has been engaged in the development of medical products based on its proprietary self-assembling peptide technology. In the field of regenerative medicine, the Company has been promoting collaborative research with leading academic institutions worldwide. The company announced that the results of joint research with Harvard University, employing the Company's self-assembling peptide "RADA16," was recently published in the internationally renowned scientific journal Science. This publication marks a advancement in addressing fundamental challenges in cardiac regenerative therapy. Conventional transplantation of iPSC-derived cardiomyocytes has been hindered by the occurrence of life-threatening arrhythmias caused by abnormal automaticity (spontaneous contraction) of the transplanted cells. In this study, the company successfully suppressed this arrhythmogenic automaticity through co-administration of the Company's self- assemblingling peptide. Furthermore, using a technology of flexible nanoelectronics, company were the first in the world to visualize how transplanted cells electrically integrate and synchronize with host cardiac tissue. In addition, the study demonstrated that the peptide significantly accelerated the maturation of the transplanted cells, shifting their gene expression profile from a fetal-like to an adult-like state, and markedly enhanced the organization of sarcomeres, the contractile units of cardiomyocytes. In addition, functional vascularization, which was difficult to verify, was clearly confirmed. The transplanted tissue formed functional anastomoses with host vasculature, establishing a stable supply of oxygen and nutrients, which greatly improved cell survival. This technology is expected not only to accelerate the practical application of iPSC-based therapies for heart disease, but also to drive progress in regenerative medicine for various tissues requiring vascularization. This research was conducted within the existing development budget and will have no impact on full-year financial forecast or current mid-term business plan. The Company will continue to collaborate globally with leading academic institutions to contribute to solving unmet medical needs and to bring new medical value to society through innovation in regenerative medicine.
공시 • Sep 233-D Matrix, Ltd. to Report Q2, 2026 Results on Dec 11, 20253-D Matrix, Ltd. announced that they will report Q2, 2026 results on Dec 11, 2025
공시 • Jul 113-D Matrix, Ltd. announced that it has received ¥1.103184 billion in funding from CVI Investments, Inc.On July 10, 2025, 3-D Matrix Co., Ltd. closed the transaction.
공시 • Jul 093-D Matrix, Ltd. to Report Q1, 2026 Results on Sep 11, 20253-D Matrix, Ltd. announced that they will report Q1, 2026 results on Sep 11, 2025
공시 • Jun 123-D Matrix, Ltd., Annual General Meeting, Jul 24, 20253-D Matrix, Ltd., Annual General Meeting, Jul 24, 2025.
공시 • Apr 113-D Matrix, Ltd. to Report Fiscal Year 2025 Results on Jun 12, 20253-D Matrix, Ltd. announced that they will report fiscal year 2025 results on Jun 12, 2025
공시 • Jan 173-D Matrix, Ltd. to Report Q3, 2025 Results on Mar 13, 20253-D Matrix, Ltd. announced that they will report Q3, 2025 results on Mar 13, 2025
공시 • Oct 293-D Matrix, Ltd. to Report Q2, 2025 Results on Dec 12, 20243-D Matrix, Ltd. announced that they will report Q2, 2025 results on Dec 12, 2024
공시 • Aug 033-D Matrix, Ltd. to Report Q1, 2025 Results on Sep 12, 20243-D Matrix, Ltd. announced that they will report Q1, 2025 results on Sep 12, 2024
공시 • Jun 153-D Matrix, Ltd., Annual General Meeting, Jul 25, 20243-D Matrix, Ltd., Annual General Meeting, Jul 25, 2024.
공시 • May 173-D Matrix, Ltd. to Report Fiscal Year 2024 Results on Jun 13, 20243-D Matrix, Ltd. announced that they will report fiscal year 2024 results on Jun 13, 2024
공시 • Apr 043-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.On April 4, 2024, 3-D Matrix, Ltd., closed the transaction.
공시 • Mar 203-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement to issue 260,000 stock acquisition rights at an issue price of ¥87 per stock acquisition right for the gross proceeds of ¥22,620,000 on March 19, 2024. The transaction will include participation from returning investor, CVI Investments, Inc. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company.
공시 • Mar 013-D Matrix, Ltd. to Report Q3, 2024 Results on Mar 13, 20243-D Matrix, Ltd. announced that they will report Q3, 2024 results on Mar 13, 2024
공시 • Nov 133-D Matrix, Ltd. to Report Q2, 2024 Results on Dec 13, 20233-D Matrix, Ltd. announced that they will report Q2, 2024 results on Dec 13, 2023
공시 • Sep 023-D Matrix, Ltd. to Report Q1, 2024 Results on Sep 13, 20233-D Matrix, Ltd. announced that they will report Q1, 2024 results on Sep 13, 2023
공시 • Jun 163-D Matrix, Ltd., Annual General Meeting, Jul 27, 20233-D Matrix, Ltd., Annual General Meeting, Jul 27, 2023.
공시 • May 103-D Matrix, Ltd. to Report Fiscal Year 2023 Results on Jun 14, 20233-D Matrix, Ltd. announced that they will report fiscal year 2023 results on Jun 14, 2023
공시 • Feb 163-D Matrix, Ltd. to Report Q3, 2023 Results on Mar 17, 20233-D Matrix, Ltd. announced that they will report Q3, 2023 results on Mar 17, 2023